CNM-Au8
Other
Evidence outlook · regulatory review
Amyotrophic Lateral Sclerosis: application submitted to FDA
Clene submits an NDA to the FDA seeking accelerated approval of CNM-Au8 for ALS (2026-10). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.
Latest reported trial: NCT04414345 · Phase 2/3 · missed primary endpoint · grade pending
Also in development:Multiple Sclerosis · Phase 2/3Parkinson's Disease · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
RESCUE-ALS NCT04098406 · Amyotrophic Lateral Sclerosis RESCUE-ALS was a randomized, double-blind, placebo-controlled Phase 2 trial that gave 45 people with early ALS on riluzole either CNM-Au8 30 mg or placebo for 36 weeks. The single primary endpoint was the percent change in the summated motor unit number index (MUNIX), a nerve-conduction biomarker. The difference from placebo was 7.7% (95% CI -11.9 to 27.3, p=0.43), so the primary endpoint was missed. The sponsor highlights a later survival analysis, which was exploratory. Sources: Vucic et al., EClinicalMedicine 2023, and the CT.gov posted results. Registry: NCT04098406 | 2 | Electromyography Measures of Disease Progression. (36 weeks) 2021-07-13 | Percent change in summated MUNIX score at Week 36: LS mean difference 7.7% vs placebo (95% CI -11.9 to 27.3), p=0.43 (Vucic et al., EClinicalMedicine 2023; CT.gov posted results). | not yet graded | link ↗ |
View 1 more trial
NCT04414345 NCT04414345 · Amyotrophic Lateral Sclerosis Regimen C of the HEALEY ALS Platform Trial randomized 161 people with ALS to CNM-Au8 or matching placebo under full blinding for 24 weeks. The primary endpoint was the rate of decline on the ALS Functional Rating Scale, modelled together with survival. The disease rate ratio was 0.97 (95% credible interval 0.783 to 1.175), and the trial found no benefit or harm on the primary or secondary endpoints, so the primary endpoint was missed. Sources: the JAMA 2025 trial report and the CT.gov posted results. Registry: NCT04414345 | 2/3 | Disease Progression as Assessed by the ALSFRS-R Total Score (Baseline to 24 Weeks); Mortality Event Rate (Baseline to 24 Weeks) 2022-04-13 | ALS disease progression (ALSFRS-R slope with survival, shared-parameter model) at 24 weeks, combined CNM-Au8 doses vs placebo: disease rate ratio 0.97 (95% credible interval 0.783 to 1.175), posterior probability of benefit 0.65 (Bayesian), no benefit shown (JAMA 2025). CT.gov posts a rate ratio of 0.98 (0.797 to 1.188). | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 2/3 (2)
What this study did
What this study did
Phase 2 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (1)
What this study did
Appears in other studies (1)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 2/3 (1)
What this study did
Competitive landscape
This drug's own stage for Amyotrophic Lateral Sclerosis: Phase 2/3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| CNM-Au8: this drug | Phase 2/3 | Nanoparticle | mitochondrial energy metabolism | not yet graded | No reviewed efficacy summary in this indication | |
| Edaravone (Radicava ORS) | Approved | Small molecule | Reactive oxygen species (ROS) | Weak signal | Featured results are safety only in this race | |
| Tofersen (Qalsody) | Approved | RNA / oligonucleotide | SOD1 | Partial signal | No reviewed efficacy summary in this indication | |
| Masitinib | Phase 3 | Small molecule | KIT (c-Kit), also PDGFR and Lyn/Fyn kinases | not yet graded | No reviewed efficacy summary in this indication | |
| Ulefnersen | Phase 3 | RNA / oligonucleotide | FUS | Reliable signal | NCT04768972: FUSION (NCT04768972): ulefnersen met its primary endpoint, a joint rank (win-ratio style) analysis of time to death/permanent ventilation, time to rescue, and change in ALSFRS-R score to Day 505 vs placebo; p=0.0005. | |
| CB03-154 | Phase 2/3 | Small molecule | KCNQ2/3 (Kv7.2/7.3) potassium channel (opener) | not yet graded | No reviewed efficacy summary in this indication | |
| Ibudilast | Phase 2/3 | Small molecule | PDE4 and PDE10; macrophage migration inhibitory factor (MIF) | not yet graded | No reviewed efficacy summary in this indication | |
| Tazbentetol (SPG302) | Phase 2/3 | Small molecule | Dendritic spine density | Weak signal | Featured results are safety only in this race | |
| Dazucorilant | Phase 2 | Small molecule | Glucocorticoid receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Foralumab | Phase 2 | Monoclonal antibody | CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| ALN-SOD | Phase 1/2 | RNA / oligonucleotide | SOD1 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent